Exact Sciences Corporation
EXAS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.96 | -8.12 | 0.62 |
| FCF Yield | 0.72% | 0.24% | -5.02% | -1.78% |
| EV / EBITDA | -15.84 | 521.68 | -25.97 | -23.72 |
| Quality | ||||
| ROIC | -19.03% | -3.56% | -10.01% | -9.78% |
| Gross Margin | 69.55% | 70.49% | 68.27% | 74.04% |
| Cash Conversion Ratio | -0.20 | -0.76 | 0.36 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.80% | 12.26% | 11.80% | 26.34% |
| Free Cash Flow Growth | 133.48% | 107.29% | -84.04% | -429.96% |
| Safety | ||||
| Net Debt / EBITDA | -2.73 | 66.57 | -5.23 | -3.18 |
| Interest Coverage | -32.80 | -8.80 | -42.68 | -66.44 |
| Efficiency | ||||
| Inventory Turnover | 5.17 | 5.79 | 5.59 | 4.37 |
| Cash Conversion Cycle | 64.57 | 53.81 | 51.60 | 74.32 |